研究设计与统计指南

订阅

MedSci主页 / 所有栏目 / 研究设计与统计指南

治疗绝经后骨质疏松症创新药临床试验技术指导原则（2021年）

2021-01-14 国家药品监督管理局药品审评中心（CDE） NMPA

骨质疏松症

为鼓励用于治疗绝经后骨质疏松症创新药临床研发，进一步规范和指导临床试验设计，提供可参照的技术规范，在国家药品监督管理局的部署下，药审中心组织制定了《治疗绝经后骨质疏松症创新药临床试验技术指导原则》（见

中文标题：

治疗绝经后骨质疏松症创新药临床试验技术指导原则（2021年）

发布机构：

国家药品监督管理局药品审评中心（CDE）

发布日期：

2021-01-14

简要介绍：

为鼓励用于治疗绝经后骨质疏松症创新药临床研发，进一步规范和指导临床试验设计，提供可参照的技术规范，在国家药品监督管理局的部署下，药审中心组织制定了《治疗绝经后骨质疏松症创新药临床试验技术指导原则》（见附件）。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》（药监综药管〔2020〕9号）要求，经国家药品监督管理局审查同意，现予发布，自发布之日起施行。
       特此通告。
                                                                                                                           国家药品监督管理局药品审评中心
                                                                                                                                         2021年1月14日

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=19e631c0020532de, title=治疗绝经后骨质疏松症创新药临床试验技术指导原则（2021年）, enTitle=, guiderFrom=NMPA, authorId=0, author=, summary=为鼓励用于治疗绝经后骨质疏松症创新药临床研发，进一步规范和指导临床试验设计，提供可参照的技术规范，在国家药品监督管理局的部署下，药审中心组织制定了《治疗绝经后骨质疏松症创新药临床试验技术指导原则》（见, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心（CDE）, associationIntro=国家药品监督管理局药品审评中心（CDE）, copyright=0, guiderPublishedTime=Thu Jan 14 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>为鼓励用于治疗绝经后骨质疏松症创新药临床研发，进一步规范和指导临床试验设计，提供可参照的技术规范，在国家药品监督管理局的部署下，药审中心组织制定了《治疗绝经后骨质疏松症创新药临床试验技术指导原则》（见附件）。根据《国家药监局综合司关于印发药品技术指导原则发布程序的通知》（药监综药管〔2020〕9号）要求，经国家药品监督管理局审查同意，现予发布，自发布之日起施行。<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 特此通告。<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 国家药品监督管理局药品审评中心<br />&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2021年1月14日</p>, tagList=[TagDto(tagId=644, tagName=骨质疏松症)], categoryList=[CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21067, categoryName=梅斯医学-骨质疏松网, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=30, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3065, appHits=123, showAppHits=0, pcHits=756, showPcHits=2942, likes=0, shares=12, comments=8, approvalStatus=1, publishedTime=Tue Feb 09 14:42:06 CST 2021, publishedTimeString=2021-01-14, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=fbzhang, createdTime=Tue Feb 09 14:39:41 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 05:54:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214735, encodeId=2c741214e3511, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:48:34 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181484, encodeId=534e118148482, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85885577571, createdName=ms9000001761409400, createdTime=Thu Jan 06 19:56:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007936, encodeId=ebb1100e936b2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73744898739, createdName=593865972, createdTime=Sat Aug 14 23:40:54 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972978, encodeId=42399e2978a3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3b5380537, createdName=ms7000000119469804, createdTime=Sat Jun 12 00:18:37 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924440, encodeId=349a9244400d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=450391467, createdName=freesimon, createdTime=Sat Feb 13 12:21:40 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2022-04-26 su_yi_fei

    ***

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214735, encodeId=2c741214e3511, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:48:34 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181484, encodeId=534e118148482, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85885577571, createdName=ms9000001761409400, createdTime=Thu Jan 06 19:56:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007936, encodeId=ebb1100e936b2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73744898739, createdName=593865972, createdTime=Sat Aug 14 23:40:54 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972978, encodeId=42399e2978a3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3b5380537, createdName=ms7000000119469804, createdTime=Sat Jun 12 00:18:37 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924440, encodeId=349a9244400d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=450391467, createdName=freesimon, createdTime=Sat Feb 13 12:21:40 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2022-01-06 ms9000001761409400

    好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214735, encodeId=2c741214e3511, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:48:34 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181484, encodeId=534e118148482, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85885577571, createdName=ms9000001761409400, createdTime=Thu Jan 06 19:56:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007936, encodeId=ebb1100e936b2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73744898739, createdName=593865972, createdTime=Sat Aug 14 23:40:54 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972978, encodeId=42399e2978a3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3b5380537, createdName=ms7000000119469804, createdTime=Sat Jun 12 00:18:37 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924440, encodeId=349a9244400d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=450391467, createdName=freesimon, createdTime=Sat Feb 13 12:21:40 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-08-14 593865972

    好

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1214735, encodeId=2c741214e3511, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:48:34 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181484, encodeId=534e118148482, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85885577571, createdName=ms9000001761409400, createdTime=Thu Jan 06 19:56:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007936, encodeId=ebb1100e936b2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73744898739, createdName=593865972, createdTime=Sat Aug 14 23:40:54 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972978, encodeId=42399e2978a3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3b5380537, createdName=ms7000000119469804, createdTime=Sat Jun 12 00:18:37 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924440, encodeId=349a9244400d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=450391467, createdName=freesimon, createdTime=Sat Feb 13 12:21:40 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-06-12 ms7000000119469804

    学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1214735, encodeId=2c741214e3511, content=***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=427d4785086, createdName=su_yi_fei, createdTime=Tue Apr 26 19:48:34 CST 2022, time=2022-04-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1181484, encodeId=534e118148482, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85885577571, createdName=ms9000001761409400, createdTime=Thu Jan 06 19:56:56 CST 2022, time=2022-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007936, encodeId=ebb1100e936b2, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73744898739, createdName=593865972, createdTime=Sat Aug 14 23:40:54 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972978, encodeId=42399e2978a3, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a3b5380537, createdName=ms7000000119469804, createdTime=Sat Jun 12 00:18:37 CST 2021, time=2021-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=924440, encodeId=349a9244400d, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=450391467, createdName=freesimon, createdTime=Sat Feb 13 12:21:40 CST 2021, time=2021-02-13, status=1, ipAttribution=)]
    2021-02-13 freesimon

    学习了

    0

相关指南

中医药防治原发性骨质疏松症专家共识（2020）

中国老年学和老年医学学会(CAGG,China Association of Gerontology and Geriatrics) 骨质疏松分会 · 2020-12-30

2020版中国糖皮质激素性骨质疏松症防治专家共识

中国医师协会风湿免疫科医师分会 · 2021-01-15

《治疗绝经后骨质疏松症创新药临床试验技术指导原则（征求意见稿）》

国家药品监督管理局药品审评中心（CDE） · 2020-10-21

男性骨质疏松症诊疗指南

中华医学会骨质疏松和骨矿盐疾病分会(Chinese Medical Association) · 2020-10-30

骨质疏松症中西医结合诊疗指南

中国中西医结合学会(CAIM,Chinese Association of Integrative Medicine) 骨伤科专业委员会 · 2019-12-03

骨质疏松症康复指南

中国康复医学会(Chinese Association Of Rehabilitation Medicine) · 2019-11-30